![surmount-1 tirzepatide non-diabetic obesity trial In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Delivers in SURMOUNT-2 -](https://lookaside.instagram.com/seo/google_widget/crawler/?media_id=3585945231426876830)
surmount-1 tirzepatide non-diabetic obesity trial In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Delivers in SURMOUNT-2 -
Description
How does Tirzepatide work vs
![surmount-1 tirzepatide non-diabetic obesity trial In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Delivers in SURMOUNT-2 -](https://cardiacwire.com/wp-content/uploads/2023/05/tirzepatide-5.8.2023-scaled-e1683241658726.jpg)
There are no scheduled video calls or in-person visits unless specifically needed
![surmount-1 tirzepatide non-diabetic obesity trial In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Delivers in SURMOUNT-2 -](https://preview.redd.it/surmount-1-three-year-obesty-diabetes-prevention-outcomes-v0-2zzx3yzzbczd1.jpeg?width=1170&format=pjpg&auto=webp&s=a9eed5073a7b7d8fdd5eb262666da9df6bf99264)
Protein metabolism, which requires adequate B6, intensifies when the body is breaking down both dietary protein and its own tissues during weight loss
![surmount-1 tirzepatide non-diabetic obesity trial In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Delivers in SURMOUNT-2 -](https://www.nejm.org/cms/asset/67482ba8-0712-42b2-8a78-c184135fcbe8/nejmoa2416394_f1.jpg)
The cost of medical weight loss varies depending on the specific treatment plan and duration
![surmount-1 tirzepatide non-diabetic obesity trial In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Delivers in SURMOUNT-2 -](https://ars.els-cdn.com/content/image/1-s2.0-S2667368126000045-ga1.jpg)
Loss of Muscle Mass Muscle tissue produces heat even at rest
![surmount-1 tirzepatide non-diabetic obesity trial In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Delivers in SURMOUNT-2 -](https://static.wixstatic.com/media/1f382d_67b017bcb17540bab22652766148f880~mv2.jpg/v1/fill/w_568,h_170,al_c,lg_1,q_80,enc_avif,quality_auto/1f382d_67b017bcb17540bab22652766148f880~mv2.jpg)
Jalleh, R
![surmount-1 tirzepatide non-diabetic obesity trial In an earlier analysis of the trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide Delivers in SURMOUNT-2 -](https://zappyhealth.com/wp-content/uploads/2026/02/Tirzepatide-1-scaled.webp)
